ALERT:

Non-Small Cell Lung Cancer Clinical Trial 2014-084

[LCID Study Number: 2014-084]

A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

The purpose of this research study is to compare any good and bad effects of using the study drug, crizotinib (also known as XALKORI), after completion of surgery and, in some cases, after chemotherapy and/or radiation therapy for ALK-positive non-small cell lung cancer.

Disease/Condition: Non-Small Cell Lung Cancer

Department: Hematology and Oncology

Location(s): Lahey Hospital & Medical Center (Burlington), Lahey Medical Center, Peabody; Lahey Lexington, Lahey Arlington, Lahey Nashua

Primary Contact Email: [email protected]

Primary Contact Phone: 781-744-3421

Protocol #: 2014-084
Principal Investigator(s): Paul J Hesketh
Study Coordinator(s): Carol Bovest
Trial Phase: Sponsor Initiated Study Phase 3